New hope for young patients with spreading bone cancer
NCT ID NCT06820957
Summary
This trial is testing whether adding two new drugs, irinotecan and regorafenib, to standard chemotherapy works better for young patients with Ewing sarcoma that has spread. It aims to see if this combination helps patients live longer without their cancer returning. The study is for patients aged 1 to 50 who are newly diagnosed with this rare and aggressive cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROUND CELL SARCOMA WITH EWSR1-NON-ETS FUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BI-LO Charities Children's Cancer Center
Greenville, South Carolina, 29605, United States
-
Children's Hospital of Alabama
Birmingham, Alabama, 35233, United States
-
East Tennessee Childrens Hospital
Knoxville, Tennessee, 37916, United States
-
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826, United States
-
Lurie Children's Hospital-Chicago
Chicago, Illinois, 60611, United States
-
NYU Langone Hospital - Long Island
Mineola, New York, 11501, United States
-
Prisma Health Richland Hospital
Columbia, South Carolina, 29203, United States
-
Saint Christopher's Hospital for Children
Philadelphia, Pennsylvania, 19134, United States
-
Saint Jude Midwest Affiliate
Peoria, Illinois, 61637, United States
Conditions
Explore the condition pages connected to this study.